Treatment of depressive symptoms in patients with heart failure

Comparison of the effectiveness of Escitalopram and Bupropion in treatment of depression symptome patient with heart failure in double blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190525043700N5

Enrollment

Registered

2022-12-29

Start date

2023-01-20

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Major depressive disorder, single episode, mild

Interventions

Intervention 1: Intervention group 1: Patients in the treatment group with Bupropion (Zibutrin) (Tehran Daru Pharmaceutical Group) (75mg) start as 1 tablet daily (which can be increased up to 150mg ac

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years old With heart failure Depressive Disorder (Based on the questionnaire) Willingness to participate in the study

Exclusion criteria

Exclusion criteria: Patient with cognitive impairment Mental retardation History of substance use Bipolar disorder History of depression before heart failure History of seizure

Design outcomes

Primary

Measure	Time frame
Patient´s depressive condition. Timepoint: Before intervention (first visit) ,the end of the fourth week (second visit), the end of the eighth week (third visit), the end of the twelfth week (the fourth visit). Method of measurement: Beck's depression inventory and Hamilton Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRomina Hamzehpour

Babol University of Medical Sciences

r.hamzehpour@mubabol.ac.ir+98 11 3229 1951

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026